HELLERUP, Denmark, March 29, 2021 /PRNewswire/ — UNION therapeutics A/S (UNION) in the present day introduced that the Nationwide Institute for Well being Analysis (NIHR) within the UK has granted Pressing Public Well being (UPH) prioritization to the PROTECT-V trial – a platform research investigating UNION’s niclosamide-based therapy candidate for COVID-19 in kidney sufferers.
Scientific trials granted UPH prioritization by the NIHR are deemed critically necessary within the battle towards COVID-19 and can thus obtain infrastructure assist permitting expedited recruitment for the research. NIHR is an entity beneath the Division of Well being & Social Care of the UK authorities.
UPH prioritization will allow streamlined website arrange throughout the UK, and facilitate speedy affected person recruitment because of NIHR useful resource and medical analysis community assist being out there.
“We’re happy that our COVID-19 program has achieved this necessary recognition via the UPH prioritization of the PROTECT-V research because it paves the way in which for a sooner and extra environment friendly conduct of the trial,” mentioned UNION co-founder, Professor Morten Sommer.
“The PROTECT-V trial is testing our product, a niclosamide-based nasal spray (UNI91103), in kidney sufferers, who might require extra safety from COVID-19 along with vaccination. Contemplating the medical wants inside this high-risk affected person group, it is important that the trial will be capable to roll out in an expeditated method,” Professor Sommer concluded.
The PROTECT-V trial is led by the Cambridge College Hospitals NHS Basis Belief and the College of Cambridge and entails researchers and sufferers from throughout the UK.
UNI91103 is a niclosamide based mostly nasal spray in growth for prophylaxis and therapy of COVID-19. SARS-CoV-2, the virus inflicting COVID-19, has been discovered to copy most quickly in nasal epithelial cells, and the sinonasal tract is considered an necessary website for an infection in addition to transmission. Niclosamide has been recognized as a potent inhibitor of SARS-CoV-2 and has been demonstrated to forestall deadly outcomes in a murine problem mannequin of COVID-19 when administered intranasally. UNI91103 nasal spray is in growth as a stand-alone product in addition to together with UNION therapeutics’ inhalation therapy product (UNI91104).
About UNION therapeutics A/S
UNION therapeutics A/S is a privately held, medical stage, pharmaceutical firm devoted to the event of novel therapies for inflammatory and infectious illnesses. The Firm is engaged on two complementary chemistry courses spanning immunology and microbiology, with a number of candidates in medical growth. UNION is headquartered in Hellerup (Denmark) and is managed by an skilled worldwide group. For extra info, please go to: www.uniontherapeutics.com.
Chief Monetary Officer
Tel: +45 2381 5487
Electronic mail: email@example.com
Tel: +44 781 8430877
Electronic mail: firstname.lastname@example.org
This info was delivered to you by Cision http://news.cision.com
The next recordsdata can be found for obtain:
SOURCE UNION therapeutics